DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)

South Korea flag South Korea · Delayed Price · Currency is KRW
20,850
-550 (-2.57%)
May 20, 2026, 3:30 PM KST
Market Cap940.56B +37.7%
Revenue (ttm)926.88B +14.1%
Net Income66.02B +7.8%
EPS1,475.00 +7.8%
Shares Out45.11M
PE Ratio14.14
Forward PE10.60
Dividend200.00 (0.93%)
Ex-Dividend DateDec 29, 2025
Volume295,626
Average Volume417,257
Open21,300
Previous Close21,400
Day's Range20,350 - 21,350
52-Week Range16,260 - 31,250
Betan/a
RSI35.20
Earnings DateMay 22, 2026

About DongKook Pharmaceutical

DongKook Pharmaceutical Co., Ltd. provides pharmaceutical products in South Korea and internationally. It produces active pharmaceutical ingredients, including propofol, streptokinase, and teicoplanin; disposable syringes; and pills, capsules, and ointments, as well as small volume parentral, large volume parentral, and lyophilized injectable drug injections. The company also offers Teicon, Durakinase, and Lorelin Depot injections; produces various natural product materials, such as black cohosh extract and magnolia extract comprises ETIZM and ... [Read more]

Sector Healthcare
Founded 1968
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 086450
Full Company Profile

Financial Performance

In 2025, DongKook Pharmaceutical's revenue was 926.88 billion, an increase of 14.12% compared to the previous year's 812.17 billion. Earnings were 66.02 billion, an increase of 8.64%.

Financial Statements